Spain (ES)

Consensus statement on the problem of terminology in psychological interventions using the internet or digital components (2020) Smoktunowicz E, Barak A, Andersson G, Banos RM, Berger T, Botella C, Dear BF, et al. Journal article Impact of the Energetic Landscape on Polariton Condensates' Propagation along a Coupler (2020) Rozas E, Beierlein J, Yulin A, Klaas M, Suchomel H, Egorov O, Shelykh IA, et al. Journal article RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS (2020) Seibold M, Stuehmer T, Kremer N, Mottok A, Scholz CJ, Schlosser A, Leich E, et al. Journal article Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study (2020) Dimopoulos MA, Lonial S, White D, Moreau P, Weisel K, San-Miguel J, Shpilberg O, et al. Journal article Understanding the UV luminescence of zinc germanate: The role of native defects (2020) Dolado J, Martinez-Casado R, Hidalgo P, Gutierrez R, Dianat A, Cuniberti G, Dominguez-Adame F, et al. Journal article Strict comparison for C∗ -algebras arising from almost finite groupoids (2020) Ara P, Bonicke C, Bosa J, Li K Journal article Dust and gas absorption in the high mass X-ray binary IGR J16318-4848 (2020) Ballhausen R, Lorenz M, Fuerst F, Pottschmidt K, Corrales L, Tomsick JA, Kühnel M, et al. Journal article Characteristics of the first 615 patients enrolled in Pacific R: A study of the first real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (2020) Girard N, Fietkau R, Garassino M, Garrido P, Field JK, Peters S, Smit HJM, et al. Conference contribution EPIK-B3: A phase III, randomised, double-blind (DB), placebo (PBO)-controlled study of alpelisib (ALP) plus nab-paclitaxel (nabPTX) in advanced triple-negative breast cancer (TNBC) with either PIK3CA mutation or phosphatase and tensin homolog (PTEN) loss without PIK3CA mutation (2020) Sharma P, Farooki A, Fasching P, Loi S, Peterson K, Prat A, Tripathy D, et al. Conference contribution Pooled analysis of patient (pt)-reported quality of life (QOL) in the MONALEESA (ML)-2,-3, and-7 trials of ribociclib (RIB) plus endocrine therapy (ET) to treat hormone receptore-positive, HER2-negative (HR+/HER2L) advanced breast cancer (ABC) (2020) Fasching P, Bardia A, Nusch A, Jerusalem G, Chan A, El Saghir N, Alba E, et al. Conference contribution